The treatment of @entity43 with a combination of chemotherapy, radiotherapy, and radiosensitizer: report of a pilot study from the National XXXX Institute.

@entity1 @entity43 @entity137 @entity390 @entity8712 @entity882 @entity353 @entity5 @entity900 @entity786 @entity391 @entity1431 @entity11558
Twenty-eight @entity1 with @entity43 were treated with combined chemotherapy-radiotherapy employing a unique protocol. Four cycles of @entity786 and @entity11558 alternated with four cycles of concurrent @entity900 , whole abdominal radiotherapy, and intraperitoneal @entity8712 . The entire treatment program lasted six months. Clinical complete responses were seen in 50% of the @entity1 with an overall response rate of 61%. Pathologic complete response (PCR) confirmed at second look surgery occurred in 18% of the group (5 @entity1 ). Median survival of the entire group was 15.2 months with all PCR's alive NED. This outcome was no different than our previous experience with combination chemotherapy alone. @entity137 seen included @entity1431 , @entity882 , @entity390 , @entity391 , and @entity353 . However, these side effects were manageable. Two non- @entity5 deaths occurred. This study demonstrates the feasibility of combining drug and radiation therapy concurrently in the treatment of @entity43 ; further research is needed to explore different sequencing and dose levels that could improve the outcome.
